m+Medelevator.RU
← Поиск публикаций
bioRxiv : the preprint server for biology · 2025

Antibody responses against bacterial glycans affinity mature and diversify in germinal centers.

СтатьяПрепринтНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Fryer Holly A, Pitt Catherine, Frost Hannah R, Kandhari Nitika, Byars Sean, Lim Pailene S, Nguyen Trang T, Chheng Kaneka, Caltabiano Natalie, Whitcombe Alana L, Hamelink Julianne, Andrew Dean, Lloyd Gareth, Wilson-Boyd Brian, Slee Nicola, Ballantine Jodie, Vasani Sarju, Girling Kathryn, Gubbels Liam, Levi Eric, Davies Karen, Tangye Stuart, Noonan Jonathan, Moreland Nicole J, Quast Isaak, Robinson Marcus J, Scally Stephen W, Neeland Melanie, Shanthikumar Shivanthan, Osowicki Joshua, Tarlinton David M, Steer Andrew C, Boyle Michelle J, Hill Danika L

Аннотация

Anti-carbohydrate antibodies (Abs) play crucial roles in pathogen control, but their generation remains poorly understood. By studying responses to Streptococcus pyogenes in humans, we reveal that the glycan-targeted response shifts from IgM towards IgG and IgA memory with age and antigen exposure across blood, spleen, and tonsils. Both natural colonization and controlled human infection with S. pyogenes increased class-switched B cells, with evidence of within-clone switching. Glycan-specific B cells readily participated in germinal center (GC) responses and showed robust somatic hypermutation despite a molecular signature consistent with receiving reduced T cell help. We conclude that mucosal pathogen encounters elicit glycan responses that class-switch, evolve and diversify through the GC. These findings reveal how age and infection history can influence the quality, quantity, and isotype use of glycan-specific B cells, with implications for the design and schedule of glycan-containing vaccines.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты